Advisory Board November 20, 2024
Recent research has found that a majority of American adults qualify for the weight-loss drug semaglutide. And with obesity rates in the United States continuing to rise, drugmakers are lobbying employers to cover the expensive drug, arguing it will save them money in the long run.
5 catalysts that will impact the future of weight management drugs
Most Americans qualify for semaglutide
Semaglutide was first approved under the brand name Ozempic in 2017 as a treatment for Type 2 diabetes and was later approved in 2021 under the brand name Wegovy as a treatment for adults with obesity or for overweight adults with at least one weight-related condition like high blood pressure or Type 2 diabetes.
A recent study published...
Today's Sponsors
Today's Sponsor